In vivo detection of amyloid-β deposits using heavy chain antibody fragments in a transgenic mouse model for alzheimer's disease

PLoS ONE

Volumn 7, Issue 6, 2012, Pages

  Nabuurs, Rob J A ^a   Rutgers, Kim S ^a   Welling, Mick M ^a   Metaxas, Athanasios ^b   de Backer, Maaike E ^a   Rotman, Maarten ^a   Bacskai, Brian J ^c   van Buchem, Mark A ^a   van der Maarel, Silvère M ^a   van der Weerd, Louise ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; ANTIBODY; HEAVY CHAIN NI3A FRAGMENT ANTIBODY; HEAVY CHAIN PA2H FRAGMENT ANTIBODY; MANNITOL; PENTETATE INDIUM IN 111; TECHNETIUM 99M; UNCLASSIFIED DRUG; IMMUNOGLOBULIN FRAGMENT; IMMUNOGLOBULIN HEAVY CHAIN;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; CONTROLLED STUDY; FLUORESCENCE; HUMAN; HUMAN TISSUE; IN VIVO STUDY; ISOTOPE LABELING; KIDNEY CLEARANCE; MOLECULAR IMAGING; MOUSE; NONHUMAN; PLASMA CLEARANCE; PROTEIN ANALYSIS; TRANSGENIC MOUSE; VASCULAR AMYLOIDOSIS; AMYLOID PLAQUE; ANIMAL; AUTORADIOGRAPHY; BLOOD; DISEASE MODEL; FLUORESCENT ANTIBODY TECHNIQUE; HALF LIFE TIME; IMMUNOLOGY; METABOLISM; PATHOLOGY; PROTEIN BINDING; SPECIES DIFFERENCE; TISSUE DISTRIBUTION;

ANIMALIA; MUS; MUS MUSCULUS;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; AUTORADIOGRAPHY; BLOOD-BRAIN BARRIER; DISEASE MODELS, ANIMAL; FLUORESCENT ANTIBODY TECHNIQUE; HALF-LIFE; HUMANS; IMMUNOGLOBULIN FRAGMENTS; IMMUNOGLOBULIN HEAVY CHAINS; MICE; MICE, TRANSGENIC; PLAQUE, AMYLOID; PROTEIN BINDING; SPECIES SPECIFICITY; TISSUE DISTRIBUTION;

EID: 84861851074     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0038284     Document Type: Article

References (41)

1. Duyckaerts C, Delatour B, Potier MC, (2009) Classification and basic pathology of Alzheimer disease. Acta Neuropathol 118: 5-36 doi:10.1007/s00401-009-0532-1.
2. Smith EE, Greenberg SM, (2009) Beta-amyloid, blood vessels, and brain function. Stroke 40: 2601-2606 doi:10.1161/STROKEAHA.108.536839.
3. Weller RO, Preston SD, Subash M, Carare RO, (2009) Cerebral amyloid angiopathy in the aetiology and immunotherapy of Alzheimer disease. Alzheimers Res Ther 1: 6 doi:10.1186/alzrt6.
4. Jicha GA, (2009) Is passive immunization for Alzheimer's disease 'alive and well' or 'dead and buried'? Expert Opin Biol Ther 9: 481-491 doi:10.1517/14712590902828285.
5. Greenberg SM, Bacskai BJ, Hyman BT, (2003) Alzheimer disease's double-edged vaccine. Nat Med 9: 389-390 doi:10.1038/nm847.
6. Jack CR Jr, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, et al. (2010) Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 9: 119-128 doi:10.1016/S1474-4422(09)70299-6.
7. Frisoni GB, Fox NC, Jack CR Jr, Scheltens P, Thompson PM, (2010) The clinical use of structural MRI in Alzheimer disease. Nat Rev Neurol 6: 67-77 doi:10.1038/nrneurol.2009.215.
8. Johnson KA, Gregas M, Becker JA, Kinnecom C, Salat DH, et al. (2007) Imaging of amyloid burden and distribution in cerebral amyloid angiopathy. Ann Neurol 62: 229-234 doi:10.1002/ana.21164.
9. Rutgers KS, van Remoortere A, van Buchem MA, Verrips CT, Greenberg SM, et al. (2009) Differential recognition of vascular and parenchymal beta amyloid deposition. Neurobiol Aging doi:10.1016/j.neurobiolaging.2009.11.012.
10. Hamers-Casterman C, Atarhouch T, Muyldermans S, Robinson G, Hamers C, et al. (1993) Naturally occurring antibodies devoid of light chains. Nature 363: 446-448 doi:10.1038/363446a0.
11. Harmsen MM, De Haard HJ, (2007) Properties, production, and applications of camelid single-domain antibody fragments. Appl Microbiol Biotechnol 77: 13-22 doi:10.1007/s00253-007-1142-2.
12. Rutgers KS, Nabuurs RJ, van den Berg SA, Schenk GJ, Rotman M, et al. (2011) Transmigration of beta amyloid specific heavy chain antibody fragments across the in vitro blood-brain barrier. Neuroscience doi:10.1016/j.neuroscience.2011.05.076.
13. Jankowsky JL, Slunt HH, Ratovitski T, Jenkins NA, Copeland NG, et al. (2001) Co-expression of multiple transgenes in mouse CNS: a comparison of strategies. Biomol Eng 17: 157-165.
14. Welling MM, Paulusma-Annema A, Balter HS, Pauwels EK, Nibbering PH, (2000) Technetium-99m labelled antimicrobial peptides discriminate between bacterial infections and sterile inflammations. Eur J Nucl Med 27: 292-301.
15. Welling MM, Korsak A, Gorska B, Oliver P, Mikolajczak R, et al. (2005) Kit with technetium-99m labelled antimicrobial peptide UBI 29-41 for specific infection detection. Journal of Labelled Compounds & Radiopharmaceuticals 48: 683-691 doi:10.1002/jlcr.961.
16. Klunk WE, Bacskai BJ, Mathis CA, Kajdasz ST, McLellan ME, et al. (2002) Imaging Abeta plaques in living transgenic mice with multiphoton microscopy and methoxy-X04, a systemically administered Congo red derivative. J Neuropathol Exp Neurol 61: 797-805.
17. Skoch J, Dunn A, Hyman BT, Bacskai BJ, (2005) Development of an optical approach for noninvasive imaging of Alzheimer's disease pathology. J Biomed Opt 10: 11007 doi:10.1117/1.1846075.
18. Robbins EM, Betensky RA, Domnitz SB, Purcell SM, Garcia-Alloza M, et al. (2006) Kinetics of cerebral amyloid angiopathy progression in a transgenic mouse model of Alzheimer disease. J Neurosci 26: 365-371 doi:10.1523/JNEUROSCI.3854-05.2006.
19. Wadghiri YZ, Sigurdsson EM, Wisniewski T, Turnbull DH, (2005) Magnetic resonance imaging of amyloid plaques in transgenic mice. Methods Mol Biol 299: 365-379.
20. Natte R, Maat-Schieman ML, Haan J, Bornebroek M, Roos RA, et al. (2001) Dementia in hereditary cerebral hemorrhage with amyloidosis-Dutch type is associated with cerebral amyloid angiopathy but is independent of plaques and neurofibrillary tangles. Ann Neurol 50: 765-772.
21. Duyckaerts C, Potier MC, Delatour B, (2008) Alzheimer disease models and human neuropathology: similarities and differences. Acta Neuropathol 115: 5-38 doi:10.1007/s00401-007-0312-8.
22. Guntert A, Dobeli H, Bohrmann B, (2006) High sensitivity analysis of amyloid-beta peptide composition in amyloid deposits from human and PS2APP mouse brain. Neuroscience 143: 461-475 doi:10.1016/j.neuroscience.2006.08.027.
23. van Groen T, Kiliaan AJ, Kadish I, (2006) Deposition of mouse amyloid beta in human APP/PS1 double and single AD model transgenic mice. Neurobiol Dis 23: 653-662 doi:10.1016/j.nbd.2006.05.010.
24. Bussiere T, Bard F, Barbour R, Grajeda H, Guido T, et al. (2004) Morphological characterization of Thioflavin-S-positive amyloid plaques in transgenic Alzheimer mice and effect of passive Abeta immunotherapy on their clearance. Am J Pathol 165: 987-995.
25. Richardson JA, Burns DK, (2002) Mouse models of Alzheimer's disease: a quest for plaques and tangles. ILAR J 43: 89-99.
26. Adlard PA, Bush AI, (2006) Metals and Alzheimer's disease. J Alzheimers Dis 10: 145-163.
27. Leskovjan AC, Lanzirotti A, Miller LM, (2009) Amyloid plaques in PSAPP mice bind less metal than plaques in human Alzheimer's disease. Neuroimage 47: 1215-1220 doi:10.1016/j.neuroimage.2009.05.063.
28. Gainkam LO, Huang L, Caveliers V, Keyaerts M, Hernot S, et al. (2008) Comparison of the biodistribution and tumor targeting of two 99mTc-labeled anti-EGFR nanobodies in mice, using pinhole SPECT/micro-CT. J Nucl Med 49: 788-795 doi:10.2967/jnumed.107.048538.
29. Huang L, Muyldermans S, Saerens D, (2010) Nanobodies(R): proficient tools in diagnostics. Expert Rev Mol Diagn 10: 777-785 doi:10.1586/erm.10.62.
30. Behr TM, Goldenberg DM, Becker W, (1998) Reducing the renal uptake of radiolabeled antibody fragments and peptides for diagnosis and therapy: present status, future prospects and limitations. Eur J Nucl Med 25: 201-212.
31. Muruganandam A, Tanha J, Narang S, Stanimirovic D, (2002) Selection of phage-displayed llama single-domain antibodies that transmigrate across human blood-brain barrier endothelium. FASEB J 16: 240-242 doi:10.1096/fj.01-0343fje.
32. Abulrob A, Sprong H, Van Bergen en HP, Stanimirovic D, (2005) The blood-brain barrier transmigrating single domain antibody: mechanisms of transport and antigenic epitopes in human brain endothelial cells. J Neurochem 95: 1201-1214 doi:10.1111/j.1471-4159.2005.03463.x.
33. Coppieters K, Dreier T, Silence K, de Haard H, Lauwereys M, et al. (2006) Formatted anti-tumor necrosis factor alpha VHH proteins derived from camelids show superior potency and targeting to inflamed joints in a murine model of collagen-induced arthritis. Arthritis Rheum 54: 1856-1866 doi:10.1002/art.21827.
34. Tijink BM, Laeremans T, Budde M, Stigter-van WM, Dreier T, et al. (2008) Improved tumor targeting of anti-epidermal growth factor receptor Nanobodies through albumin binding: taking advantage of modular Nanobody technology. Mol Cancer Ther 7: 2288-2297 doi:10.1158/1535-7163.MCT-07-2384.
35. Koffie RM, Farrar CT, Saidi LJ, William CM, Hyman BT, et al. (2011) Nanoparticles enhance brain delivery of blood-brain barrier-impermeable probes for in vivo optical and magnetic resonance imaging. Proc Natl Acad Sci U S A 108: 18837-18842 doi:10.1073/pnas.1111405108.
36. Chartier A, Raz V, Sterrenburg E, Verrips CT, van der Maarel SM, et al. (2009) Prevention of oculopharyngeal muscular dystrophy by muscular expression of Llama single-chain intrabodies in vivo. Hum Mol Genet 18: 1849-1859 doi:10.1093/hmg/ddp101.
37. Dumoulin M, Last AM, Desmyter A, Decanniere K, Canet D, et al. (2003) A camelid antibody fragment inhibits the formation of amyloid fibrils by human lysozyme. Nature 424: 783-788 doi:10.1038/nature01870.
38. Lafaye P, Achour I, England P, Duyckaerts C, Rougeon F, (2009) Single-domain antibodies recognize selectively small oligomeric forms of amyloid beta, prevent Abeta-induced neurotoxicity and inhibit fibril formation. Mol Immunol 46: 695-704 doi:10.1016/j.molimm.2008.09.008.
39. Verheesen P, de Kluiver A, van Koningsbruggen S, de Brij M, De Haard HJ, et al. (2006) Prevention of oculopharyngeal muscular dystrophy-associated aggregation of nuclear polyA-binding protein with a single-domain intracellular antibody. Hum Mol Genet 15: 105-111 doi:10.1093/hmg/ddi432.
40. Stijlemans B, Conrath K, Cortez-Retamozo V, van Xong H, Wyns L, et al. (2004) Efficient targeting of conserved cryptic epitopes of infectious agents by single domain antibodies. African trypanosomes as paradigm. J Biol Chem 279: 1256-1261 doi:10.1074/jbc.M307341200.
41. Klunk WE, Lopresti BJ, Ikonomovic MD, Lefterov IM, Koldamova RP, et al. (2005) Binding of the positron emission tomography tracer Pittsburgh compound-B reflects the amount of amyloid-beta in Alzheimer's disease brain but not in transgenic mouse brain. J Neurosci 25: 10598-10606 doi:10.1523/JNEUROSCI.2990-05.2005.